News on haematological malignancies
ASH 2022: Novel drug shows early promise in treating multiple myeloma
A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma,…
Browsing: Haematology
ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses in patients with heavily pretreated multiple myeloma
Results have been announced for the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf…
ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy
Researchers observed encouraging response rates in older or high-risk patients with newly diagnosed acute myeloid…
ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL
The chemotherapy-free regimen of ponatinib and blinatumomab achieved high response rates and reduced the need…
ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS
The latest results of a Phase II study evaluating the addition of venetoclax to the…
ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax demonstrate robust efficacy and sustained response in older, unfit patients with previously untreated chronic lymphocytic leukaemia
New four-year follow-up results from the Phase 3 GLOW study (Abstract #93), were announced during…
ASH 2022: Next-generation targeted therapy zanubrutinib found superior to ibrutinib for CLL and SLL
The targeted drug zanubrutinib showed superior efficacy with fewer side effects than ibrutinib in the…
ASH 2022: Blinatumomab further improves survival among B-lineage ALL patients with a good prognosis
The immunotherapy blinatumomab was found to improve overall survival for patients with no measurable residual…
ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in newly diagnosed, transplant-ineligible MM
The Phase 3 MAIA study’s updated analyses reported progression-free survival, minimal residual disease negativity, overall…
ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities
During the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13…